Abstract
A key principle of clinical studies and case reports is that they should reflect the demographics and epidemiology of the patient population concerned. Here, we have compiled a diverse group of clinical cases of generalized pustular psoriasis (GPP) to showcase the differences in GPP presentation in patients worldwide. We attempt to capture the broad spectrum of clinical presentations of GPP and showcase the diversity of the patient population. The patients included in this series are diverse in age, genetic background, skin phototype and medical history. Moreover, they present with a variety of clinical courses of GPP and different degrees of systemic involvement, and experience flares triggered by different inciting factors. The key learnings from this case series may support physicians in identifying and managing patients with this rare and multifaceted disease that can affect patients both physically and psychologically.
| Original language | English |
|---|---|
| Pages (from-to) | 1284-1295 |
| Number of pages | 12 |
| Journal | Experimental Dermatology |
| Volume | 32 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2023 |
Keywords
- case study
- generalized pustular psoriasis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Experimental Dermatology, Vol. 32, No. 8, 08.2023, p. 1284-1295.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Diversity in the clinical presentation of generalized pustular psoriasis (GPP)
T2 - a series of case vignettes from around the world
AU - Choon, Siew Eng
AU - Elewski, Boni E.
AU - Fujita, Hideki
AU - Geng, Songmei
AU - van de Kerkhof, Peter
AU - Mburu, Sicily
AU - Puig, Lluís
AU - Romiti, Ricardo
AU - Venturini, Marina
N1 - Funding Information: Isabella Goldsbrough, PhD, of OPEN Health Communications (London, UK) provided writing, editorial and formatting support, which was contracted and funded by Boehringer Ingelheim. Esther Roé, MD, of the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) took care of patient 1 and contributed clinical data for their case report. Bin Peng, MD, resident of the Second Hospital Affiliated to Xi'an Jiaotong University, helped in the collection of the history and clinical images for patient 6. The authors met criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Funding Information: This publication was supported and funded by Boehringer Ingelheim, as part of the initiative PIONEERS™ Partnering for Innovation and Excellence in Rare Skin Diseases. Funding Information: SEC declares paid activities as an advisor, speaker or consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sanofi and UCB. BE is an investigator for AbbVie, Amgen (previously Celgene), AnaptysBio, Bausch Health (formerly Valeant Pharmaceuticals), Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, LEO Pharma, Menlo, Merck, Novartis, Pfizer, Regeneron, Sun Pharmaceutical Industries, UCB and Vanda; and is a consultant for Amgen (previously Celgene), Arcutis, Bausch Health (formerly Valeant Pharmaceuticals), Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, LEO Pharma, Novartis and UCB. HF declares receiving honoraria or fees for serving on advisory boards, as a speaker, and as a consultant, as well as grants as an investigator, from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi‐Sankyo, Eisai, Eli Lilly, Janssen Pharmaceuticals, Japan Blood Products Organization, JMEC, Kaken, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Nihon Pharmaceutical, Novartis, Otsuka Pharmaceutical, Sanofi, Sato Pharmaceutical, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, UCB and Ushio. SG has no conflict of interest to disclose. PvdK received fees for consultancy service or lectureships from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Janssen, LEO Pharma, Novartis and UCB. SM has not received individual compensation, however, on behalf of the IFPA, has received fees for consultancy services and/or lectureships from Almirall, Boehringer Ingelheim, Novartis and UCB. In the past 12 months, the IFPA has accepted grants and funding from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer and UCB. LP has received consultancy/speaker's honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sandoz, Sanofi and UCB. RR declares receiving honoraria as a scientific consultant, speaker or clinical study investigator for AbbVie, Boehringer Ingelheim, Galderma, Janssen‐Cilag, Eli Lilly, LEO Pharma, Novartis, Pfizer, Pierre‐Fabre, Sanofi, Teva and UCB. MV has received consultancy fees or lectureships from AbbVie, Almirall, Amgen, Eli Lilly, Galderma, LEO Pharma, Novartis, Pierre Fabre and UCB. Publisher Copyright: © 2023 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
PY - 2023/8
Y1 - 2023/8
N2 - A key principle of clinical studies and case reports is that they should reflect the demographics and epidemiology of the patient population concerned. Here, we have compiled a diverse group of clinical cases of generalized pustular psoriasis (GPP) to showcase the differences in GPP presentation in patients worldwide. We attempt to capture the broad spectrum of clinical presentations of GPP and showcase the diversity of the patient population. The patients included in this series are diverse in age, genetic background, skin phototype and medical history. Moreover, they present with a variety of clinical courses of GPP and different degrees of systemic involvement, and experience flares triggered by different inciting factors. The key learnings from this case series may support physicians in identifying and managing patients with this rare and multifaceted disease that can affect patients both physically and psychologically.
AB - A key principle of clinical studies and case reports is that they should reflect the demographics and epidemiology of the patient population concerned. Here, we have compiled a diverse group of clinical cases of generalized pustular psoriasis (GPP) to showcase the differences in GPP presentation in patients worldwide. We attempt to capture the broad spectrum of clinical presentations of GPP and showcase the diversity of the patient population. The patients included in this series are diverse in age, genetic background, skin phototype and medical history. Moreover, they present with a variety of clinical courses of GPP and different degrees of systemic involvement, and experience flares triggered by different inciting factors. The key learnings from this case series may support physicians in identifying and managing patients with this rare and multifaceted disease that can affect patients both physically and psychologically.
KW - case study
KW - generalized pustular psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85151917564&partnerID=8YFLogxK
U2 - 10.1111/exd.14794
DO - 10.1111/exd.14794
M3 - Article
C2 - 36999936
AN - SCOPUS:85151917564
SN - 0906-6705
VL - 32
SP - 1284
EP - 1295
JO - Experimental Dermatology
JF - Experimental Dermatology
IS - 8
ER -